Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD known ✓ | Q03181 | 6/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.67 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.53 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL31472849 | 1.00 | GSR (0.67) | GSRFFAR4FFAR1AKR1B1CYP2D6 | |
| Decanoic Acid SCHEMBL597983 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| Myristic Acid SCHEMBL2909091 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| Stearic Acid SCHEMBL7176001 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| Decanoic Acid SCHEMBL6374907 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| SCHEMBL18344245 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| Octanoic Acid SCHEMBL7178164 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| Octanoic Acid SCHEMBL7178169 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| Palmitic Acid SCHEMBL597984 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 | |
| Decanoic Acid SCHEMBL6374906 | 0.98 | GSR (0.65) | GSRFFAR4FFAR1ALDH1A1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210001023-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS-FREE LTD (IL) | 2021-01-07 | — | — | US | claimed |
| EP-3746151-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS-FREE LTD. (IL) | 2020-12-09 | — | — | EP | claimed |
| US-11975132-B2 | Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof | PLAS-FREE LTD (IL) | 2024-05-07 | — | — | US | disclosed |
| US-20210001023-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS-FREE LTD (IL) | 2021-01-07 | — | — | US | disclosed |
| EP-3746151-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS-FREE LTD. (IL) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210001023-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLG, FGB, PLAU | PPARD 3785/4885GSR 4418/4885FFAR4 1762/4885 |
| US-11975132-B2 | Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof | PLG, FGB, PLAU | PPARD 3785/4885GSR 4418/4885FFAR4 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.